BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 29187643)

  • 1. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase.
    Puzzo F; Colella P; Biferi MG; Bali D; Paulk NK; Vidal P; Collaud F; Simon-Sola M; Charles S; Hardet R; Leborgne C; Meliani A; Cohen-Tannoudji M; Astord S; Gjata B; Sellier P; van Wittenberghe L; Vignaud A; Boisgerault F; Barkats M; Laforet P; Kay MA; Koeberl DD; Ronzitti G; Mingozzi F
    Sci Transl Med; 2017 Nov; 9(418):. PubMed ID: 29187643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase.
    Cagin U; Puzzo F; Gomez MJ; Moya-Nilges M; Sellier P; Abad C; Van Wittenberghe L; Daniele N; Guerchet N; Gjata B; Collaud F; Charles S; Sola MS; Boyer O; Krijnse-Locker J; Ronzitti G; Colella P; Mingozzi F
    Mol Ther; 2020 Sep; 28(9):2056-2072. PubMed ID: 32526204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease.
    Keeler AM; Zieger M; Todeasa SH; McCall AL; Gifford JC; Birsak S; Choudhury SR; Byrne BJ; Sena-Esteves M; ElMallah MK
    Hum Gene Ther; 2019 Jan; 30(1):57-68. PubMed ID: 29901418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscle-specific, liver-detargeted adeno-associated virus gene therapy rescues Pompe phenotype in adult and neonate Gaa
    Sellier P; Vidal P; Bertin B; Gicquel E; Bertil-Froidevaux E; Georger C; van Wittenberghe L; Miranda A; Daniele N; Richard I; Gross DA; Mingozzi F; Collaud F; Ronzitti G
    J Inherit Metab Dis; 2024 Jan; 47(1):119-134. PubMed ID: 37204237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade.
    Han SO; Li S; Brooks ED; Masat E; Leborgne C; Banugaria S; Bird A; Mingozzi F; Waldmann H; Koeberl D
    Hum Gene Ther; 2015 Jan; 26(1):26-35. PubMed ID: 25382056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Therapy for Pompe Disease: The Time is now.
    Colella P; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defects.
    Colella P; Sellier P; Gomez MJ; Biferi MG; Tanniou G; Guerchet N; Cohen-Tannoudji M; Moya-Nilges M; van Wittenberghe L; Daniele N; Gjata B; Krijnse-Locker J; Collaud F; Simon-Sola M; Charles S; Cagin U; Mingozzi F
    EBioMedicine; 2020 Nov; 61():103052. PubMed ID: 33039711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.
    Fraites TJ; Schleissing MR; Shanely RA; Walter GA; Cloutier DA; Zolotukhin I; Pauly DF; Raben N; Plotz PH; Powers SK; Kessler PD; Byrne BJ
    Mol Ther; 2002 May; 5(5 Pt 1):571-8. PubMed ID: 11991748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II.
    Franco LM; Sun B; Yang X; Bird A; Zhang H; Schneider A; Brown T; Young SP; Clay TM; Amalfitano A; Chen YT; Koeberl DD
    Mol Ther; 2005 Nov; 12(5):876-84. PubMed ID: 16005263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
    Han SO; Li S; Bird A; Koeberl D
    Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salmeterol enhances the cardiac response to gene therapy in Pompe disease.
    Han SO; Li S; Koeberl DD
    Mol Genet Metab; 2016 May; 118(1):35-40. PubMed ID: 27017193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ability of adeno-associated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice.
    Ziegler RJ; Bercury SD; Fidler J; Zhao MA; Foley J; Taksir TV; Ryan S; Hodges BL; Scheule RK; Shihabuddin LS; Cheng SH
    Hum Gene Ther; 2008 Jun; 19(6):609-21. PubMed ID: 18500944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter.
    Sun B; Zhang H; Franco LM; Brown T; Bird A; Schneider A; Koeberl DD
    Mol Ther; 2005 Jun; 11(6):889-98. PubMed ID: 15922959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease.
    Sun B; Li S; Bird A; Yi H; Kemper A; Thurberg BL; Koeberl DD
    J Gene Med; 2010 Nov; 12(11):881-91. PubMed ID: 20967919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression.
    Sun B; Zhang H; Bird A; Li S; Young SP; Koeberl DD
    J Gene Med; 2009 Oct; 11(10):913-20. PubMed ID: 19621331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
    Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A
    Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity.
    Eggers M; Vannoy CH; Huang J; Purushothaman P; Brassard J; Fonck C; Meng H; Prom MJ; Lawlor MW; Cunningham J; Sadhu C; Mavilio F
    EMBO Mol Med; 2022 Jan; 14(1):e13968. PubMed ID: 34850579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice.
    Qiu K; Falk DJ; Reier PJ; Byrne BJ; Fuller DD
    Mol Ther; 2012 Jan; 20(1):21-7. PubMed ID: 22008916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy.
    McCall AL; Stankov SG; Cowen G; Cloutier D; Zhang Z; Yang L; Clement N; Falk DJ; Byrne BJ
    Curr Gene Ther; 2019; 19(3):197-207. PubMed ID: 31223086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease.
    Zhang P; Sun B; Osada T; Rodriguiz R; Yang XY; Luo X; Kemper AR; Clay TM; Koeberl DD
    Hum Gene Ther; 2012 May; 23(5):460-72. PubMed ID: 22260439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.